Citi Initiates BridgeBio at Neutral: Why the Cardiomyopathy Story Isn’t a Slam Dunk

BridgeBio Pharma (NASDAQ:BBIO) received a Neutral initiation from Citi Neutral on Tuesday, reflecting a measured stance on ...

How Encaleret’s NDA and New Acoramidis Milestones Could Reframe BridgeBio Pharma (BBIO) Investors’ Outlook

BridgeBio Pharma recently filed a New Drug Application with the FDA for encaleret in autosomal dominant hypocalcemia type 1, following Phase 3 CALIBRATE results showing rapid, durable improvements in ...
Nasdaq

Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

- Attruby demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date: - In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related ...
Nasdaq

BridgeBio Pharma Reports Strong Early Demand for Attruby and Updates on Phase 3 Clinical Trials

BridgeBio reports strong demand for Attruby post-FDA approval and enrollment completion in three Phase 3 trials, with significant financial backing. BridgeBio Pharma, Inc. announced significant ...
Pharmaceutical Technology on MSN

BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial

An indirect comparison highlights Attruby’s potential as the better TTR stabiliser over Pfizer’s tafamidis in frontline ...
Monthly Prescribing Reference

Attruby Approved for Cardiomyopathy of Transthyretin-Mediated Amyloidosis

Near-complete in vitro TTR stabilization was observed as early as day 28 and through completion of a 30-month study of patients with ATTR-CM. The Food and Drug Administration (FDA) has approved ...
Benzinga.com

FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market

On Friday, the FDA approved BridgeBio Pharma, Inc.’s (NASDAQ:BBIO) Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM to reduce ...
Seeking Alpha

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study

-ATTRibute-CM, BridgeBio’s Phase 3 clinical trial of acoramidis in patients with ATTR-CM, achieved statistical significance in reducing the risk of ACM or first CVH versus placebo in ATTRv-CM patients ...

Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure

Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p<0.001), which is associated ...
MedPage Today

Acoramidis Snags FDA Approval for ATTR Cardiomyopathy

Acoramidis (Attruby) gained FDA approval for treating wild-type or variant transthyretin (TTR) amyloidosis cardiomyopathy (ATTR-CM), BridgeBio Pharma announced. Offering patients near-complete TTR ...
MarketWatch

BridgeBio Selects PANTHERx(R) Rare Specialty Pharmacy for Distribution of Attruby(TM) (acoramidis)

PITTSBURGH, Nov. 26, 2024 /PRNewswire/ -- PANTHERx(R) Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce that it was selected by ...